Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation (ERADICATE--AF) Trial

The objective of this trial is to determine the role of renal sympathetic denervation in the prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.

Inclusion Criteria:

• Age ≥ 18 years of age
• History of PAF and plans for a guideline-supported catheter ablation procedure. Paroxysmal AF is defined as AF with duration of 30 secs to 7 days.
• History of significant hypertension (defined as SBP ≥130 mm Hg and/or DBP ≥80 mmHg) and receiving treatment with at least one anti-hypertensive medication
• Renal vasculature accessible as determined by pre-procedural renal MRA
• Willingness to comply with all post-procedural follow-up requirements and to sign informed consent

Exclusion Criteria:

• Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to all anticoagulation)
• Prior left atrial ablation for an atrial arrhythmia
• NYHA class IV congestive heart failure
• Pers or longstanding Pers AF (duration > 7 days)
• Renal artery anatomy that is ineligible for treatment
• An estimated glomerular filtration rate (eGFR) < 45mL/min/1.73m2, using the MDRD calculation
• Life expectancy <1 year for any medical condition